What are the current JNC (Joint National Committee) hypertension treatment guidelines for adults, including blood pressure targets, first‑line medication choices, and management of resistant hypertension?

Current JNC Hypertension Guidelines

The most recent formal JNC guideline is JNC-8 from 2014, but it has been superseded by the 2025 AHA/ACC guideline which now represents the current U.S. standard for hypertension management. 1

Blood Pressure Targets

For most adults, the target is <130/80 mmHg 1. This represents a significant shift from JNC-8's more lenient targets:

• General population <60 years: <140/90 mmHg (JNC-8) vs. <130/80 mmHg (2025 AHA/ACC)
• Age ≥60 years: <150/90 mmHg (JNC-8) vs. <130/80 mmHg (2025 AHA/ACC) 2, 1
• Diabetes or CKD: <140/90 mmHg (JNC-8) vs. <130/80 mmHg (2025 AHA/ACC) 2, 1

The WHO 2022 guidelines offer a middle ground: <140/90 mmHg for general population, but <130 mmHg systolic for those with existing CVD (strong recommendation) or high cardiovascular risk (conditional recommendation) 3.

First-Line Medication Choices

Four drug classes are recommended as first-line therapy 2, 1:

1. Thiazide-type diuretics (preferably long-acting thiazide-like agents: chlorthalidone or indapamide)
2. ACE inhibitors
3. Angiotensin receptor blockers (ARBs)
4. Long-acting calcium channel blockers (CCBs)

Race-Specific Considerations

For Black patients without heart failure or CKD: Initial therapy should be a thiazide-type diuretic or CCB 4, 1. ACE inhibitors and ARBs are less effective as monotherapy in this population and carry higher risk of angioedema with ACE inhibitors 4.

For non-Black patients: Any of the four first-line classes can be used 2.

Important Caveat on Beta-Blockers

Beta-blockers are not recommended as first-line therapy in JNC-8 for uncomplicated hypertension 5, 2. However, they have compelling indications for patients with coronary artery disease, heart failure, or post-MI 6, 7.

Combination Therapy

Most patients require ≥2 medications to achieve BP control 1, 2. The 2025 AHA/ACC and WHO guidelines recommend:

• Single-pill combinations preferred to improve adherence 3, 1
• Preferred combinations: ACE inhibitor or ARB + CCB + thiazide-like diuretic 1
• Avoid: ACE inhibitor + ARB combination (no added benefit, increased harm) 3, 6

If BP is >20/10 mmHg above goal, consider initiating with two drugs simultaneously 8, 2.

Management of Resistant Hypertension

Resistant hypertension is defined as BP above goal despite 3 medications (including a diuretic) at maximum tolerated doses, or controlled BP requiring ≥4 medications 1.

Evaluation Steps

1. Exclude pseudoresistance first 1:

   • Confirm with out-of-office BP measurement (home or ambulatory monitoring)
   • Assess medication adherence
   • Review for interfering substances: NSAIDs, decongestants, licorice, excessive alcohol 1

2. Screen for secondary causes 1:

   • Primary aldosteronism (most common)
   • Obstructive sleep apnea
   • Renal artery stenosis
   • Chronic kidney disease

Treatment Algorithm

Step 1: Optimize the foundation regimen:

• ACE inhibitor or ARB + CCB + thiazide-like diuretic (chlorthalidone 12.5-25 mg or indapamide preferred over hydrochlorothiazide) 1

Step 2: Add mineralocorticoid receptor antagonist (MRA):

• Spironolactone 25-50 mg daily is the recommended fourth agent (strong evidence, eGFR ≥45 mL/min/1.73 m²) 1
• Reduces 24-hour systolic BP by 6.6-8.7 mmHg more than placebo 1
• Monitor potassium closely; contraindicated if baseline K+ >4.5 mmol/L or eGFR <45 7
• Alternative: Eplerenone if antiandrogenic side effects occur, though less effective 1

Step 3: If still uncontrolled, consider:

• Beta-blocker (particularly if not already prescribed and patient has compelling indication) 9
• Alpha-blocker (doxazosin)
• Centrally-acting agents (clonidine)

Common Pitfalls

• Using hydrochlorothiazide instead of chlorthalidone/indapamide (less effective for outcomes) 1
• Not maximizing diuretic dose before adding fourth agent
• Missing medication non-adherence as cause of apparent resistance
• Failing to screen for primary aldosteronism (present in 10-20% of resistant hypertension) 1
• Adding spironolactone without checking baseline potassium and renal function

Follow-Up Frequency

• Monthly visits after initiating or changing medications until BP at goal 3
• Every 3-6 months once controlled 3, 7

Key Differences: JNC-8 vs. Current Guidelines

The 2025 AHA/ACC guideline represents a significant departure from JNC-8's more relaxed approach. The lower BP targets (<130/80 mmHg for all adults) are based on the SPRINT trial and subsequent evidence showing reduced cardiovascular events with intensive BP control 1, 10. While JNC-8 raised the treatment threshold for elderly patients to <150/90 mmHg, this was controversial and has been reversed in current guidelines 11, 12.